Revelation Biosciences, Inc. (REVB)
Nasdaq: REVB · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2020
Who owns Revelation Biosciences, Inc.
As filed with the SECHolders of 5% or more
1
Sabby Management, LLC holds 9.6% of Common Stock, as its SCHEDULE 13G filed Jan 20, 2026 says.
Directors and officers
5
report now, of 15 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Sabby Management, LLC
SCHEDULE 13G · filed Jan 20, 2026 · Common Stock · 4.9% in Jan 2, 2025
Armistice Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common stock, par value $0.001 per share · reported falling below 5%, from 7.8% in May 15, 2026
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF
SCHEDULE 13G/A · filed Feb 12, 2024 · Common Stock, par value $0.001 per share · reported falling below 5%
What REVB reports owning in othersstakes of 5% or more, and other ties
Revelation Biosciences, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2023 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.